Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Avalo Therapeutics, Inc.
  6. News
  7. Summary
    AVTX   US05338F1084

AVALO THERAPEUTICS, INC.

(AVTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Avalo Therapeutics Appoints Chief Commercial Officer

01/11/2022 | 03:54am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
AVALO THERAPEUTICS, INC. -0.22% 0.3193 Delayed Quote.-81.22%
SWEDISH ORPHAN BIOVITRUM AB (PUBL) -1.03% 210.4 Delayed Quote.13.67%
All news about AVALO THERAPEUTICS, INC.
05/24AVALO THERAPEUTICS : Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 f..
PU
05/24AVALO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/23Mind Medicine Names Schond Greenway as CFO
MT
05/18Avalo Therapeutics Doses First Patient in Phase 2 Trial of Asthma Treatment Candidate
MT
05/18Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 ..
GL
05/18Avalo Therapeutics, Inc. Announces First Patient Dosed in the Phase 2 PEAK Trial of AVT..
CI
05/17Avalo to Present at the H.C. Wainwright Global Life Sciences Conference
GL
05/06RBC Halves Price Target on Avalo Therapeutics to $2 From $4, Noting 'Early Stage Risk W..
MT
05/05AVALO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
05/05Avalo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
CI
More news
Analyst Recommendations on AVALO THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 3,98 M - -
Net income 2022 -73,6 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,55x
Yield 2022 -
Capitalization 36,0 M 36,0 M -
Capi. / Sales 2022 9,05x
Capi. / Sales 2023 5,11x
Nbr of Employees 43
Free-Float 99,3%
Chart AVALO THERAPEUTICS, INC.
Duration : Period :
Avalo Therapeutics, Inc. Technical Analysis Chart | AVTX | US05338F1084 | MarketScreener
Technical analysis trends AVALO THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 0,32 $
Average target price 3,55 $
Spread / Average Target 1 012%
EPS Revisions
Managers and Directors
Garry Arthur Neil President & Chief Executive Officer
Christopher Sullivan Chief Financial Officer
Steven Joseph Boyd Chairman
Lisa Hegg Vice President-Research & Development Programs
Gunnar Magnus Modee Persson Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
AVALO THERAPEUTICS, INC.-81.22%36
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
SEAGEN INC.-8.54%26 026
ICON PUBLIC LIMITED COMPANY-26.61%18 478